뉴스
03 DEC 2014 | NexP™ fusion technology patent registry in EU
작성자
alteogen
작성일
2018-05-28 11:29
ALTEOGEN's patent for NexP™ fusion technology registered in EU on 3rd Dec 2014.
NexP™ fusion technology is a platfrom technology for long-acting therapeutic proteins and peptides.
With NexP™ fusion technology, we can prolong the in-vivo half life of therapeutic proteins and peptides.
NexP™ fusion technology is ALTEOGEN's proprietary technology.
NexP™ fusion technology is a platfrom technology for long-acting therapeutic proteins and peptides.
With NexP™ fusion technology, we can prolong the in-vivo half life of therapeutic proteins and peptides.
NexP™ fusion technology is ALTEOGEN's proprietary technology.